BIO International Convention - Super Session

May. 3, 2010-May. 6, 2010
McCormick Place
Chicago, IL
convention.bio.org

Description:

Campbell Alliance's 2010 Dealmakers' Intentions Survey

Campbell Alliance will have a leadership presence at this global biotech event.

Ben Bonifant, Vice President and head of our Business Development practice, will present the results of our Dealmaker's Intentions Survey during a Super Session on May 5 from 10-11:30am.

Senior management and executives in our Business Development practice will be taking meetings in a private suite #B14 within the Business Forum.

Lastly, please visit Campbell Alliance at booth # 2804 in the sponsor area.

Abstract:

Campbell Alliance's 2010 Dealmakers' Intentions Survey

Wednesday, May 5, 10:00-11:30am

The relationship between the biotechnology and pharmaceutical industries has never been more apparent – partner to survive.   For pharma, patent expirations and depleted pipelines have forced companies to look externally for growth. For biotech, the lack of financing and an uncertain regulatory and reimbursement landscape threatens the progress of innovative new therapies. In this environment, the competition for unlicensed assets has never been more intense and top dealmakers will shape the future of the industry.

Campbell Alliance and BIO are pleased to present the key findings from two unique forward-looking measures of deal-making in the industry – the Campbell Alliance 2010 Dealmaker’s Intentions Survey and the BIO 2010 Business Forum Partnering Report. 

What types of assets and target market segments will be in demand among in-licensors?
 

How are large companies communicating their areas of interest and how must emerging companies shift their approach to outreach?

Chair
Ben Bonifant, Vice President and Head, Business Development Practice, Campbell Alliance
 
Co-Chair
John Craighead, Managing Director, Investor Relations & Business Development, BIO

Paul Hastings
President & CEO
OncoMed Pharmaceuticals, Inc

BJ Bormann
Sr. Vice President
Boehringer Ingelheim GmbH

Shaun Grady
Vice President, Global Head of Transactions
AstraZeneca, Research & Development, Inc 

James Sabry, M.D., Ph.D.

Vice President, Genentech Partnering

Genentech


- - -

More Information: 
http://bio2010.bdmetrics.com/SOW-29103210/Campbell-Alliance-2010-Dealmakers-Intentions-Survey/Overview.aspx

View Entire Event Calendar

Don't Miss